Laquinimod
- The pivotal CONCERTO clinical Phase 3 study in relapsing remitting MS (RRMS) is proceeding according to plan and results are expected in 2017
- The Phase 2 studies, ARPEGGIO, which will evaluate laquinimod's potential for treatment of primary progressive MS (PPMS), and LEGATO-HD, for the treatment of Huntington's disease, are proceeding as planned
Tasquinimod
- The final results from Active Biotech's tasquinimod 10TASQ10 Phase 3 trial were presented at the ECC conference and demonstrated that while tasquinimod treatment resulted in a prolonged radiographic progression-free survival (rPFS), 7.0 vs. 4.4 months, the positive effect on rPFS did not translate into an improved OS
ISI
- Only commercial activities will be conducted from 2016
Financial summary
| MSEK | July - Sept. | Jan. - Sept. | Jan. - Dec. | |||||
| 2015 | 2014 | 2015 | 2014 | 2014 | ||||
| Net sales | 5.2 | 2.6 | 11.3 | 7.5 | 10.4 | |||
| Operating loss | -22.2 | -55.7 | -149.7 | -172.8 | -228.5 | |||
| Loss for the period | -23.4 | -56.6 | -152.7 | -174.5 | -231.5 | |||
| Loss per share, before and after dilution (SEK) | -0.26 | -0.76 | -1.70 | -2.33 | -3.02 | |||
| Cash and cash equivalents (at the end of the period) | 132.4 | 161.0 | 328.5 | |||||
For further information, please contact:
| Tomas Leanderson, President and CEO Tel: +46 (0)46 19 20 95 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 | Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund, Sweden Tel: +46 (0)46 19 20 00 Fax: +46 (0)46 19 11 00 |
The report is also available at www.activebiotech.com.
